glp 1 agonists reduce inflammation The anti-inflammatory and immunological properties of GLP-1 Receptor GLP-1 drugs calm inflammation beyond

By stimulating insulin secretion and reducing glucagon release, GLP-1 RAs lower blood sugar levels

Among Americans who have never taken GLP-1s but are considering beginning treatment in the next 12 months, 25.1% cite the pill option as the primary factor influencing their desire to begin treatment, and among the 9.3% of Americans who have discontinued GLP-1 treatments, 44.1% say they are considering resuming treatments because of pill options

The FDA accepted Novo Nordisks NDA for an oral formulation of Wegovy

and Mounjaro (tirzepatide) was approved in May 2022

[DOI] [PubMed] [Google Scholar] 338.Moghimzadeh E., Ekman R., Hakanson R., Yanaihara N., Sundler F

Thus, anti-diabetic agents that can attenuate both DKD and CVD have been awaited